Sei Investments Co. Purchases 43,753 Shares of Kestra Medical Technologies, Ltd. $KMTS

Sei Investments Co. raised its holdings in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 22.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 237,116 shares of the company’s stock after purchasing an additional 43,753 shares during the period. Sei Investments Co.’s holdings in Kestra Medical Technologies were worth $4,726,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at about $31,000. Russell Investments Group Ltd. grew its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the period. BNP Paribas Financial Markets increased its holdings in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies in the fourth quarter worth approximately $72,000. Finally, Brown Brothers Harriman & Co. increased its stake in shares of Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 13,017 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.92, for a total transaction of $311,366.64. Following the transaction, the insider owned 527,115 shares of the company’s stock, valued at approximately $12,608,590.80. This represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 5,391 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80. Following the completion of the sale, the chief financial officer directly owned 93,891 shares of the company’s stock, valued at approximately $2,234,605.80. This trade represents a 5.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 143,127 shares of company stock worth $3,240,392 over the last ninety days. 5.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

KMTS has been the subject of several recent research reports. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.83.

Kestra Medical Technologies Stock Down 3.4%

Shares of KMTS opened at $25.06 on Thursday. The company has a market cap of $1.47 billion, a PE ratio of -10.36 and a beta of 0.58. Kestra Medical Technologies, Ltd. has a 52-week low of $14.10 and a 52-week high of $30.00. The business has a fifty day moving average of $22.78 and a 200 day moving average of $22.52. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million during the quarter. On average, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.